Press Releases

PRESS RELEASE April 2, 2018

Immune Pharmaceuticals Announces 2017 Financial Results

– Significant progress in 2017 positions Company for a breakthrough year – Englewood Cliffs, NJ (April 2, 2018) – Immune Pharmaceuticals, Inc. (NASDAQ: IMNP) (“Immune” or the “Company”), a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases, today announced financial results for the year and quarter ended December 31, […]

Keep Reading

PRESS RELEASE March 12, 2018

Immune Pharmaceuticals Announces Acceptance of Abstract at 2018 Pre-IID Pemphigus and Pemphigoid Symposium

ENGLEWOOD CLIFFS, NJ–(Marketwired – March 12, 2018) – Immune Pharmaceuticals, Inc.(IMNP) (“Immune” or the “Company”) a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases, announced today the acceptance of an abstract for a poster presentation at the 2018 Pre-IID Pemphigus and Pemphigoid Symposium: “A New Era of Translation and […]

Keep Reading

PRESS RELEASE February 27, 2018

Immune Pharmaceuticals Announces Outcome of Annual Meeting of Stockholders

Englewood Cliffs, NJ (February 27, 2018) – Immune Pharmaceuticals, Inc. (NASDAQ; IMNP) (“Immune” or the “Company”) a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases, announced today that Proposal 4 – Ratification of the Reverse Stock Split set forth in the Company’s Definitive Proxy Statement filed with the Securities […]

Keep Reading

PRESS RELEASE February 20, 2018

Immune Pharmaceuticals Announces Adjournment of Annual Meeting of Stockholders and Provides Business Update

5 of 6 proposals pass with shareholder approval Meeting adjourned solely with respect to Proposal 4 – Ratification of the Reverse Stock Split Company outlines key corporate and clinical milestones for 201 Englewood Cliffs, NJ (February 20, 2018) – Immune Pharmaceuticals, Inc. (NASDAQ; IMNP) (“Immune” or the “Company”) a biopharmaceutical company developing novel therapeutic agents […]

Keep Reading

PRESS RELEASE February 6, 2018

Immune Pharmaceuticals to Present at the BIO CEO & Investor Conference on February 12, 2018

Englewood Cliffs, NJ- February 6, 2018 – Immune Pharmaceuticals Inc. (NASDAQ: IMNP) a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases, announced that its CEO, Elliot Maza, will present at the BIO CEO & Investor Conference, to be held February 12-13 at the New York Marriott Marquis in New York, […]

Keep Reading

PRESS RELEASE January 26, 2018

Immune Pharmaceuticals Announces Adjournment of Annual Meeting

Annual Meeting to Resume Thursday, February 15, 2018 Englewood Cliffs, NJ – January 26, 2018 – Immune Pharmaceuticals Inc. (NASDAQ: IMNP), a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases, announced today that it adjourned its Annual Meeting of Stockholders, scheduled for and convened on January 25, 2018. The […]

Keep Reading

PRESS RELEASE January 23, 2018

Immune Pharmaceuticals to Present at the NobleCon 14 Annual Investor Conference on January 30, 2018

Englewood Cliffs, New Jersey, USA- January 23, 2018 – Immune Pharmaceuticals Inc. (NASDAQ: IMNP) a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases, announced that its CEO, Elliot Maza, will present at NobleCon14- Noble Capital Markets’ Fourteenth Annual Investor Conference, to be held January 29-30 at the W Hotel in […]

Keep Reading

PRESS RELEASE January 10, 2018

Immune Pharmaceuticals Announces Acceptance of Late-Breaking Abstract at the American Academy of Dermatology Annual Meeting 2018

Oral Presentation to Include Positive Interim Results from its Ongoing Phase 2 Trial of Bertilimumab in Bullous Pemphigoid Englewood Cliffs, NJ- January 10, 2018 – Immune Pharmaceuticals Inc. (NASDAQ: IMNP) (the “Company”) a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases, announced today that an abstract detailing positive interim […]

Keep Reading

PRESS RELEASE January 4, 2018

Immune Pharmaceuticals to Present at the Biotech Showcase™ Annual Conference on January 10, 2018

Englewood Cliffs, NJ- January 4,2018 – Immune Pharmaceuticals Inc. (NASDAQ: IMNP), a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases, announced that it will present at Biotech Showcase ™ 2018, to be held January 8–10 during the most important week in healthcare investment forums at the Hilton San Francisco […]

Keep Reading